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Abstract The heterodimeric molecule MRP-8/MRP-14 
(SlOOA8/S100A9) is abundantly expressed in circulating mon-
ocytes and neutrophils. We report here an homology between the 
C-terminal 'tail' region of MRP-14 (SlOOA9) and sequences 
within the plasma protein, high molecular weight kininogen 
(HMWK) which are involved in binding to negatively charged 
surfaces such as kaolin. MRP-14 also binds to kaolin and is 
competitively inhibited by HMWK and by peptides corresponding 
to MRP-14 tail and the HMWK 'contact' regions. Furthermore 
both MRP-14 and the tail peptide inhibit the coagulation cascade 
in vitro giving functional relevance to the homology between 
MRP-14 and HMWK. At inflammatory sites, MRP-8/14 is lo-
calised to areas of close contact between myeloid cells and endo-
thelium. The results of this study identify a potential binding 
region in MRP-14 and suggest that it could function by interfer-
ing with fibrin formation at sites of leukocyte transendothelial 
migration. 
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1. Introduction 
The proteins MRP-8 (SI00A8) and MRP-14 (SlOOA9) are 
members of the SlOO family abundantly expressed as a hetero-
dimeric complex in the cytosol of circulating monocytes and 
neutrophils [1-5). The presence of two of the helix-loop-helix, 
calcium-bmding motifs (known as EF-hands) in both MRP-8 
and MRP-14 is a general characteristic of S I 00 family members 
which divides the proteins into an amino (N)-terminal region, 
a 'hinge' region between the two EF-hands and a carboxyl 
(C)-terminal region [5-10]. Throughout the SlOO family there 
is a significant divergence in sequence in these three regions 
which is thought to confer specificity to functions of individual 
proteins. For the limited number of SlOO proteins where func-
tion has been assigned, this hypothesis has been confirmed. The 
C-terminal region of human pll, the annex in II light chain, 
mediates complex formation with the annexin II heavy chain, 
p36 [11), while the hinge region of the murine MRP-8 homol-
ogue, CP-IO, has potent chemotactic activity [12). 
In MRP-14, the C-terminal sequence (residues 89-114) is 
unusually extended leaving the protein with an obvious 'tail', 
a feature which has highlighted this region as an area of poten-
tial functional significance. The sequence of this region has 
previously been shown to be identical to the neutrophil immo-
bilising factor (NIF) peptides [13), suggesting that this protein 
may have a role in the localisation of neutrophils and mono-
*Correspondmg author. Fax: (44) (171) 269 3093. 
cytes to inflammatory sites [14). Phosphorylation of the penul-
timate threonine residue (Thr113 of the C-terminal region occurs 
with elevated (Cac+), implicating MRP-14 in the sequence of 
events associated with neutrophil or monocyte activation [15). 
A search of protein sequences revealed homology between the 
C-terminal tail region of MRP-14 and functional domains 
within high molecular weight kininogen (HMWK) [16,17). This 
plasma protein, which has been considered to be involved in the 
initiation of intrinsic coagulation, is also likely to have addi-
tional activities. In this study, we explore the implications of the 
MRP-14 and HMWK homology and present results which 
suggest a function for MRP-14. 
2, Materials and methods 
2.1 Protelll lsolatioll and IOdinatIOn 
The MRP-8/14 complex was purified from neutrophIl cytosol usmg 
Fast Protein Liquid Chromatography ion exchange and gel filtration 
as prevIOusly described [2]. MRP-8 and MRP-14 subumts were further 
separated by C,,-reverse phase HPLC. Purified MRP-14 was iodmated 
to a specific actIVIty of 5 x 104-106 cpm . j.1g -I usmg Iodobeads as recom-
mended by the manufacturer (pIerce. UK). Kallikrein-digested, two 
chain HMWK (Enzyme Research Laboratories, UK), bovme SIOOa 
(SIOOAIIB) and SIOOb (SIOOB/B) (Sigma, USA) were obtained com-
mefClally and theIr punty confirmed by SDS-PAGE. 
2 2 O/igopeptlde synthesis 
PeptIdes spannmg the amino termmus (ammo peptide; MRP-14/5-
25), the hmge region between the two EF-hand Ca2+ -bindmg domams 
(hinge peptIde. MRP-14/45-62), the C-terminal EF-hand Ca2+ -binding 
region (EF-hand peptide; MRP-14/59-79) and the C-termmal tail re-
gion (tail peptIde; MRP-14/89-114) ofMRP-14 and the HG-rich (HG-
rich peptIde; HMWKl443-475) and HGK-nch (HGK-nch peptide; 
HMWK/493-520) regions of HMWK [17] were prepared by solid phase 
synthesis usmgj-methoxycarbonyl chemistry [18] and characterised by 
amino acid analysis and plasma desorptIOn mass spectrometry. The 
relative pOSitions of these pep tIdes are detailed m Fig I A. 
2.3 COmpetlfll'e lIlhlblllOll oj MRP-14 hllldlllg to kaohn 
Bmding to kaolm was used to measure the ability of MRP-14 to 
interact With an anionic surface Ten j.11 of mhibitory protem or peptide 
solutIOns at the concentratIOns mdicated, were mixed m 0.65 ml micro-
centrifuge tubes (Low protein bmdmg, Sorensen BIOscience Inc., USA) 
with an equal volume of kaolIn (1.25 mg'ml-' m 20 mM Tris-HCI. pH 
7.4,0.15 M NaCI: ICN BIOchemicals. USA) for 30 min at room temper-
ature prior to the addition of 2 j.1M '''I-Iabelled MRP-14 for a further 
15 mm. Supernatant was removed after centnfugatlOn at 13.000 x g for 
2 mm and the pellet counted. 
2.4. InhibitlOll oj IIltrlllslC plasma coagulatlVn assay 
An actIvated partial thromboplastin time (APTT) assay with kaolIn 
was used to assess the effect of the proteins or peptides on intrinsic 
coagulatIOn. The assay was performed as descnbed elsewhere [19] with 
mmor modificatIOn In bnef. 100 j.11 volumes of prewarmed kaolin 
(5 mg'ml- I m 0.15 M NaCl) and Bell and Alton platelet 
substItute (Diagen; Diagnostic Reagents Ltd, UK) solutions were 
mixed in a glass tube for 30 seconds prIor to the addition of 50 j.11 of 
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appropriate protein, peptide solution or Tris-buffered saline control 
and IOO.u1 of normal plasma (diluted 1:4 in PBS; Organon Teknika, 
UK). After 2 min incubation at 37°C, the mixture was reca1cified 
(100.u1 of25 mM CaCI2), and the time necessary for clot formation was 
measured on duplicate samples. 
3. Results 
3.1. Sequence homology searches 
A search of protein sequences in the Owl database (release 
22) [20] revealed significant homology between the MRP-14 tail 
and three regions within domain 5 (D5) of the light chain of 
plasma HMWK. The relative positions of these homologous 
regions are detailed in Fig. IA. The most extensive alignment 
spans 23 amino acids of the MRP-14 tail and includes 11 iden-
tical residues and 5 conserved substitutions for amino acids in 
the histidineglycine (HG)-rich region ofHMWK (residues 442~ 
464) (Fig. IB). In addition, the second half of the MRP-14 tail 
sequence can be aligned with a continuation of the HG-rich 
region (residues 465-474) and with sequence in the histidine-
glycine-Iysine- (HGK)-rich region of HMWK at residues 494~ 
504 (Fig. IB). When MRP-14 is compared with these three 
sequence alignments, only two residues do not represent either 
an identity or a conservative change. 
3.2. Purified neutrophil MRP-14 binds to kaolin 
The HG- and HGK-rich regions of HMWK both contain a 
'contact site' which independently enable HMWK to bind to 
A 
Calcium 
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anionic surfaces in model systems [17]. The similarity in se-
quence suggested that MRP-14 might also function like 
HMWK in binding to a negatively charged surface such as 
kaolin. The MRP-8 and MRP-14 complex and individual sub-
units were all purified to homogeneity from neutrophillysates 
(Fig. 2) and the MRP-14 subunit iodinated. Fig. 3A shows that 
125I-labelled MRP-14 bound to kaolin and that this binding was 
inhibited in a dose dependent manner by MRP-14, the MRP-
8114 complex and by HMWK with fifty percent inhibition 
achieved between 1 and 5 ,uM. In contrast, MRP-8 and two 
other related SlOO family members, bovine SlOOa (SlOOAIIB 
or a/3 heterodimer) and SlOOb (SlOOB/B or /3/3 homodimer) did 
not interfere with MRP-14 binding. Thus. like HMWK, mono-
mer MRP-14 was able to bind to kaolin and this activity was 
not affected by complexing with MRP-8 and was not shared 
with at least two other SlOO protein family members. Removal 
of Ca2+ (1 mM EDTA) or addition of Ca2+ (l mM) to these 
assays did not influence MRP-14 binding to kaolin (data not 
shown) suggesting that this activity functioned independently 
of the two EF-hand Ca2+ binding regions of the native MRP-14 
protein. 
3.3. C-terminal sequence of MRP-14 mediates anionic surface 
binding 
In order to test whether it was specifically the tail region of 
MRP-14 which was homologous in function as well as sequence 
to HMWK, we assessed the ability of MRP-14 to bind to kaolin 
in the presence of a series if MRP-14 and HMWK peptides (see 
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FIg. 1. Comparative homology between MRP-14 and HMWK. (a) A schematic representation of the MRP-14 and HMWK proteins illustrating the 
domain structure of each protem. The relative positions of the MRP-14 'tail' and the three regions m HMWK with which it is homologous are shown 
as dark shading. MRP-14 consists of two EF-hand type Ca2+ binding domains which divide the protein into N-terminal, 'hinge' and C-terminal 'tail' 
regIOns. HMWK is divided into the SIX domains (Dl-D6) which constitute the mature smgle chain protein prior to release of the vasoactive kinin, 
bradykinin (stnped shading), and full processing of the light chain by kallikrein cleavage. Domam 5 of HMWK contains the HG- and HGK-nch 
'contact' regIOns. The positions of peptides used in this study are indicated. (b) DetaIled amino acid comparisons of the C-terminal 'tail' sequence 
of MRP-14 (aa 89-114) and the three regions of homology in HMWK: residues 442-464 (HG-rich region); residues 465-474 (a continuation of 
sequence in the HG-rich region); and 494-504 (HGK-nch regIOn). The shaded residues are identical with those in the MRP-14 sequence; unshaded 
boxed residues indicate conservative substitutions for those in the MRP-14 sequence. 
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Fig. 2. Analysis of MRP-S/MRP-14 complex and separated subunits. 
Protems were punfied as described m section 2. Shown under reducing 
conditIOns are molecular weight standards (Amersham. Rambow 
markers: lane I): MRP-S/MRP-14 complex isolated from neutrophil 
lysates (lane 2). and separated MRP-S (lane 3): and MRP-14 subumts 
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ofMRP-8 and MRP-14were limited (~50 nM) compared with 
average concentration of plasma HMWK at -I ,LiM [22] and 
because the pep tides allowed the identification of critical re-
gions in MRP-14 which were active in the coagulation assay. 
It also allowed a comparison with pep tides covering the HG-
and HGK-rich regions ofHMWK, previously shown to inhibit 
such assays [17.19]. Figure 4 shows that coagulation was inhib-
ited by the MRP-14 tail peptide. At concentrations of this 
peptide which more than doubled the time required for clot 
A 
100 
--0-- HMWK 
----+- MRP14 
-tr- MRP8/14 
80 ---.- S100b 
--0-- MRPB 
(lane 4). AnalysIs was using SDS-1S% PAGE followed by Coomassie c 
--
S100a 
blue stammg. 0 
section 2 and Fig. I for details). Of four MRP-14 peptides, only 
the C-terminal tail peptide significantly inhibited MRP-14 kao-
lin binding in a dose dependent manner (Fig. 3B). This result 
indicates that the binding of MRP-14 to kaolin is specifically 
mediated by the extended C-terminal tail region. As this inhib-
iting activity occurs at concentrations two orders of magnitude 
higher than the intact protein, the tail peptide must depend on 
other parts of MRP-14 for optimal conformation or presenta-
tion. It is also important to note that the interaction is not 
charge dependent as the tail peptide is slightly negatively 
charged (like kaolin) under these conditions (data not shown). 
The effects of peptides spanning the HG- and HGK-rich 
regions of HMWK were also investigated. Both these peptides 
inhibited \1RP-14 binding in a dose dependent manner al-
though there was a difference in the concentration range over 
which they were effective (Fig. 3B). Notably. the HG-sequence 
peptide, displaying high homology with MRP-14 tail sequence, 
inhibited with greater efficiency than the tail peptide itself. This 
difference could reflect the fact that this peptide contains a 
duplicated HG-homologous region (see Fig. I). Collectively. 
the results show the binding of MRP-14 to negatively charged 
surfaces is specifically mediated by the C-terminal tail region 
of the protein which simulates the action of the HG-rich and 
HGK-rich regions in mediatmg the binding of HMWK to sim-
ilar surfaces. 
3.4. EHeet of MRP-14 on intrinsic coagulation 
As well as the HG-rich and HGK-rich contact regions in 
domain 5. the light chain of HMWK contains, in domain 6, 
binding sites for coagulation factor XI and prekallikrein. All 
these areas are requisite for HMWK function in the initial 
stages of intrinsic plasma coagulation [21]. As MRP-14 appears 
to share only the contact sequence. we predicted that this pro-
tein migh1 be able to interfere with the coagulation cascade. 
Therefore. in order to obtain further parallels between MRP-14 
and HMWK, we tested the effect of MRP-14, MRP-8 and the 
MRP-8114 complex in an in vitro assay of the intrinsic plasma 
coagulation. Both MRP-14 and MRP-8114 complex, but not 
MRP-8 were able to significantly delay the onset of coagulation 
(Table I). We next tested peptides from several regions of 
MRP-14. This approach was advantageous because amounts 
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Fig. 3. The C-termmal domam ofMRP-14 mediates bmding to amomc 
surfaces. The binding of 1251-labelled MRP-14 to kaohn m (a) the 
presence of varying concentrations of purified and unlabelled MRP-14. 
kallikrein-digested two cham HMWK. MRP-S. the MRP-8/MRP-14 
complex and other SIOO proteins. bovme SIOOa and bovine SlOOb or 
(b) the presence of pep tides spanmng areas of MRP-14 and HMWK. 
All points are shown as the mean of duphcate values and each curve 
IS representative of 2-4 analyses 
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Table I 
MRP-14 mhlbits plasma coagulatIOn 
Clotting time (s) P value 
Control 179 ± 3* 
MRP-14 212 ± 7 (18.4%) <0.001 
MRP-8/l4 198 ± 13 (10.6%) 0.005 
MRP-8 174 ± 4 (-2.4%) n.s. 
The effect of MRP-14, MRP-8, and the MRP-8/14 complex on assays 
ofmtrinslc plasma coagulation. Protem inhibitory activity is measured 
as the increased time necessary for clot formation and is displayed as 
mean ± standard deviation (seconds) of 4 separate expenments. Mean 
values were compared with the control using an unpaired (-test. Values 
given are for final assay protein concentratIOns of 5 x 10-8 M, which 
approximates the detectable plasma levels of the proteins in mflamma-
tory diseases [25]. 
*Values are mean ± standard deViation (seconds); bracketed values 
represent the inhibitory activity (%). 
formation, the MRP-14 hinge peptide (Fig. 4) and those from 
other regions of MRP-14 had no significant effect (data not 
shown). The inhibitory activity could be titrated but was always 
proportionately less than the inhibition produced by the HG-
region peptide from HMWK. The peptide from the HGK re-
gion ofHMWK was also inhibitory (data not shown). Thus the 
presence of the contact sequence in MRP-14 is sufficient to 
inhibit coagulation. 
4. Discussion 
Previous studies have shown that abundant amounts of 
MRP-8114 are localised on inflammatory endothelium when 
adherence and transmigration of cells is in progress [1,7]. Of 
interest is the fact that adhesion of monocytes to matrix pro-
teins fibronectin and collagen cause expression of a membrane 
form of MRP-8!9 although it is not known how it is secreted 
[23]. Such observations suggest that the MRP-8/14 complex 
might have a function in the sequence of adhesion receptor-
ligand interactions leading to leukocyte entry into inflamed 
tissues. Here we show homology between the MRP-14 C-termi-
nal tail and the two regions of HMWK which direct binding 
of the protein to anionic surfaces. Using kaolin as a model 
anionic surface, we show that the C-terminal tail sequence of 
MRP-14 performs a similar functional role. From available 
evidence, the more efficient site for HMWK binding appears 
to be contained within the HG-rich region [17,19], although it 
has previously been suggested that this area of the HMWK 
light chain has arisen by gene duplication [24]. Thus it is signif-
icant that it is with the HG-rich region that the MRP-14 tail 
is most homologous and that a peptide covering the region is 
the most effective inhibitor of MRP-14 binding to kaolin. As 
activated endothelium becomes more anionic and serves as a 
procoagulant surface [25], it may be speculated that the kaolin 
binding feature of the MRP-14 tail reflects a means by which 
the MRP-8!MRP-14 complex or the MRP-14 monomer might 
be retained at regions of endothelium involved in inflammation. 
This remains to be directly tested. 
Assays of contact activation using kaolin have been used to 
mimic the role of HMWK as a trigger for the intrinsic coagula-
tIOn pathway. The presence of either the HG- or HGK-rich 
region together with binding sites for kallekrein and factor XI 
in HMWK are essential for this function [17]. The fact that 
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MRP-14 bears only the contact sequence and lacks the other 
procoagulant features of HMWK has implications for a possi-
ble role which bound protein could adopt in vivo. Fibrin depos-
ited as a result of coagulation is anti-adhesive, apparently cre-
ating a barrier to leukocyte access to endothelium [26]. If the 
C-terminal tail-mediated binding of MRP-14 were able to 
counter fibrin deposition, more efficient interaction of leuko-
cytes with endothelium or extracellular matrix would result. Of 
interest is the fact that in our studies, monomer MRP-14 or 
MRP-8/MRP-14 complex inhibit the coagulation assay at con-
centrations approximating those detected in plasma in inflam-
matory disease [27]. A second pathway of coagulation, known 
as the extrinsic pathway, initiated by tissue factor [28] was not 
affected by MRP-14 or the MRP-8/14 complex (data not 
shown). It is thought that in vivo the extrinsic pathway is the 
initiatior of fibrin formation and the intrinsic pathway is the 
primary route for continued growth of the fibrin clot [29]. The 
possibility that both pathways could be activated at inflamma-
tory sites raises questions about their importance during leuko-
cyte adhesion and transendothelial migration and the contribu-
tion of HMWK and MRP-14. In addition, activated enzymes 
occurring downstream in the coagulation pathways are impor-
tant in a variety of processes, many of which have a bearing on 
the efficiency of inflammation. 
Accumulating evidence suggests domain 5 which contains 
the contact domain forms an important receptor recognition! 
binding region for HMWK. It is now speculated that the con-
tact sites of HMWK mediate binding to heparin [30] and by 
promoting interactions between proteinases (e.g. kallikrein or 
Factor XI) and inhibitors such as antithrombin, HMWK might 
facilitate the inactivation of these proteases [31]. Such specula-
tion suggests that, dependent on the local environment, 
HMWK is capable of both pro- and anti-coagulant activity. In 
addition domain 5 reported to interact with the leukocyte /32 
4 
3 
2 
o MRP-14 hinge 
• MRP-14 tall 
E:J HMWK HG-rtch 
-<>- MRP-14 tail titration 
300 500 750 
[Peptide] (11M) 
1000 
Fig. 4. The C-terminal tail of MRP-14 mediates the inhibition of coag-
ulation. A comparison of the effect on coagulation of the MRP-14 tail 
peptide and the HG-region peptide from HMWK at concentrations of 
500 ,liM and 1000 ,liM. Inhibitory actiVity of the MRP-14/89-114 tall 
peptide can be titrated (line graph) and is abolished at concentrations 
between 300-500 ,liM. Equivalent concentrations of the hinge peptide 
from MRP-14 were compared. CoagulatIOn times in the absence of 
peptide (control) were Within the range shown m Table I. 
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integrin Mac-l (CDllb/CDI8) [32) and provides part ofa com-
posite site [33) recognised by additional receptors on endothe-
lium [34), platelets [35) and neutrophils [36). The utilisation of 
anyone of the functional domains of HMWK upon interaction 
with these receptors is likely to have a unique effect, given the 
different roles of these cell types in the inflammatory process. 
Thus domain 5 may also direct the involvement of HMWK in 
additional activities which would have implications for the role 
of MRP-14 in inflammation. This study shows that the C-
terminal tail sequence of the SIOO family protein, MRP-14, is 
highly homologous to the contact sites ofHMWK. The homol-
ogy extends to functional similarities, in that the tail sequence 
specifically mediates the binding of MRP-14 to surfaces similar 
to those recognised by HMWK and MRP-14 can inhibit one 
activity attributable to HMWK, that of intrinsic coagulation. 
Obviously more information about the function of these pro-
teins will aid our understanding of how the contact domain 
operates in vivo. 
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